{"id":{"repo_id":"uwo","oai_identifier":"oai:uwo.scholaris.ca:20.500.14721/27536"},"canonical_url":"https://search.dev.ndltd.org/etd/uwo/oai:uwo.scholaris.ca:20.500.14721/27536","repository":{"repo_id":"uwo","name":"Western University","base_url":"https://uwo.scholaris.ca/server/oai/request"},"display":{"title":"Retinoic Acid Pathway Inhibition to Expand Human Hematopoietic Progenitor Cells with Islet Regenerative Capacity","abstract":"Cellular therapy to induce islet regeneration is emerging as a novel treatment strategy for diabetes. Umbilical cord blood (UCB)-derived hematopoietic stem/progenitor cells (HSPC) isolated by high aldehyde dehydrogenase activity (ALDHhi) reduce hyperglycemia after transplantation into streptozotocin (STZ)-treated NOD/SCID mice. However, UCB-derived ALDHhi cells are rare and expansion without the loss of regenerative function is required. We hypothesized that BMS 493, an inverse retinoic acid receptor agonist, will prevent HSPC differentiation of HSPC during expansion, generating more ALDHhi cells for therapy. ALDHhi cells expanded for 6 days with BMS 493 showed a 2.70-fold-increase in ALDHhi cells compared to untreated cells. Conditioned media from BMS 493-treated cells also increased human ß-cell proliferation in vitro. However, intrapancreatic transplantation of BMS 493-treated cells did not reduce hyperglycemia in STZ-treated NOD/SCID mice. Further characterization of HSPC expansion without differentiation is required for islet regenerative therapies.","abstract_html":"Cellular therapy to induce islet regeneration is emerging as a novel treatment strategy for diabetes. Umbilical cord blood (UCB)-derived hematopoietic stem/progenitor cells (HSPC) isolated by high aldehyde dehydrogenase activity (ALDHhi) reduce hyperglycemia after transplantation into streptozotocin (STZ)-treated NOD/SCID mice. However, UCB-derived ALDHhi cells are rare and expansion without the loss of regenerative function is required. We hypothesized that BMS 493, an inverse retinoic acid receptor agonist, will prevent HSPC differentiation of HSPC during expansion, generating more ALDHhi cells for therapy. ALDHhi cells expanded for 6 days with BMS 493 showed a 2.70-fold-increase in ALDHhi cells compared to untreated cells. Conditioned media from BMS 493-treated cells also increased human ß-cell proliferation in vitro. However, intrapancreatic transplantation of BMS 493-treated cells did not reduce hyperglycemia in STZ-treated NOD/SCID mice. Further characterization of HSPC expansion without differentiation is required for islet regenerative therapies.","abstract_has_math":false,"creators":["Elgamal, Ruth"],"institution":"The University of Western Ontario","degree_name":"M Sc","degree_level":null,"degree_discipline":"Physiology and Pharmacology","degree_department":null,"school":null,"contributors":[],"advisors":["David Hess"],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017-09-06","date_published":"2017-09-06","updated_at":"2026-07-27T21:56:13Z","subjects":["Diabetes","Stem Cells","Islet Regeneration","Retinoic Acid"],"languages":["en_ca"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/20.500.14721/27536","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["David Hess"]},{"key":"dc:creator","label":"Author","values":["Elgamal, Ruth"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-07-10T15:30:32Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-07-10T15:30:32Z"]},{"key":"dc:date.issued","label":"Date","values":["2017-09-06"]},{"key":"dc:publisher","label":"Institution","values":["The University of Western Ontario"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Physiology and Pharmacology"]},{"key":"thesis:degree_name","label":"Degree Name","values":["M Sc"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Diabetes","Stem Cells","Islet Regeneration","Retinoic Acid"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_ca"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/20.500.14721/27536"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The thesis cover page in the PDF document includes references to Western University’s previous institutional repository platform, known as Scholarship@Western, and links to that platform (beginning with ir.lib.uwo.ca). In citing or referring to this thesis, use the DOI or handle from this page instead. Sample citation: Author name, \"Thesis title.\" (Year). Western University Open Repository. https://doi.org/10.71858/123456."]},{"key":"dc:description.abstract","label":"Abstract","values":["Cellular therapy to induce islet regeneration is emerging as a novel treatment strategy for diabetes. Umbilical cord blood (UCB)-derived hematopoietic stem/progenitor cells (HSPC) isolated by high aldehyde dehydrogenase activity (ALDHhi) reduce hyperglycemia after transplantation into streptozotocin (STZ)-treated NOD/SCID mice. However, UCB-derived ALDHhi cells are rare and expansion without the loss of regenerative function is required. We hypothesized that BMS 493, an inverse retinoic acid receptor agonist, will prevent HSPC differentiation of HSPC during expansion, generating more ALDHhi cells for therapy. ALDHhi cells expanded for 6 days with BMS 493 showed a 2.70-fold-increase in ALDHhi cells compared to untreated cells. Conditioned media from BMS 493-treated cells also increased human ß-cell proliferation in vitro. However, intrapancreatic transplantation of BMS 493-treated cells did not reduce hyperglycemia in STZ-treated NOD/SCID mice. Further characterization of HSPC expansion without differentiation is required for islet regenerative therapies."]},{"key":"dc:title","label":"Title","values":["Retinoic Acid Pathway Inhibition to Expand Human Hematopoietic Progenitor Cells with Islet Regenerative Capacity"]}]}],"canonical_facts":{"dc:contributor.advisor":["David Hess"],"dc:creator":["Elgamal, Ruth"],"dc:date.accessioned":["2025-07-10T15:30:32Z"],"dc:date.available":["2025-07-10T15:30:32Z"],"dc:date.issued":["2017-09-06"],"dc:description":["The thesis cover page in the PDF document includes references to Western University’s previous institutional repository platform, known as Scholarship@Western, and links to that platform (beginning with ir.lib.uwo.ca). In citing or referring to this thesis, use the DOI or handle from this page instead. Sample citation: Author name, \"Thesis title.\" (Year). Western University Open Repository. https://doi.org/10.71858/123456."],"dc:description.abstract":["Cellular therapy to induce islet regeneration is emerging as a novel treatment strategy for diabetes. Umbilical cord blood (UCB)-derived hematopoietic stem/progenitor cells (HSPC) isolated by high aldehyde dehydrogenase activity (ALDHhi) reduce hyperglycemia after transplantation into streptozotocin (STZ)-treated NOD/SCID mice. However, UCB-derived ALDHhi cells are rare and expansion without the loss of regenerative function is required. We hypothesized that BMS 493, an inverse retinoic acid receptor agonist, will prevent HSPC differentiation of HSPC during expansion, generating more ALDHhi cells for therapy. ALDHhi cells expanded for 6 days with BMS 493 showed a 2.70-fold-increase in ALDHhi cells compared to untreated cells. Conditioned media from BMS 493-treated cells also increased human ß-cell proliferation in vitro. However, intrapancreatic transplantation of BMS 493-treated cells did not reduce hyperglycemia in STZ-treated NOD/SCID mice. Further characterization of HSPC expansion without differentiation is required for islet regenerative therapies."],"dc:identifier.uri":["https://hdl.handle.net/20.500.14721/27536"],"dc:language.iso":["en_ca"],"dc:publisher":["The University of Western Ontario"],"dc:subject":["Diabetes","Stem Cells","Islet Regeneration","Retinoic Acid"],"dc:title":["Retinoic Acid Pathway Inhibition to Expand Human Hematopoietic Progenitor Cells with Islet Regenerative Capacity"],"dc:type":["thesis"],"thesis:degree_discipline":["Physiology and Pharmacology"],"thesis:degree_name":["M Sc"]},"updated_at":"2026-07-27T21:56:13Z"}